Literature DB >> 11006269

Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells.

F Yeung1, X Li, J Ellett, J Trapman, C Kao, L W Chung.   

Abstract

Prostate-specific antigen (PSA) is expressed primarily by both normal prostate epithelium and the vast majority of prostate cancers. Increases in serum PSA during endocrine therapy are generally considered as evidence for prostate cancer recurrence or progression to androgen independence. The mechanisms by which PSA up-regulation occurs in androgen-refractory prostate cancer cells are unknown. In this study, by using LNCaP and its lineage-derived androgen-independent PSA-producing subline, C4-2, we identified two cis-elements within the 5.8-kilobase pair PSA promoter that are essential for the androgen-independent activity of PSA promoter in prostate cancer cells. First, a previously reported 440-bp androgen-responsive element enhancer core (AREc) was found to be important for the high basal PSA promoter activity in C4-2 cells. Both mutation analysis and supershift experiments demonstrated that androgen receptor (AR) binds to the AREs within the AREc and activate the basal PSA promoter activity in C4-2 cells under androgen-deprived conditions. Second, a 150-bp pN/H region was demonstrated to be a strong AR-independent positive-regulatory element of the PSA promoter in both LNCaP and C4-2 cells. Through DNase I footprinting and linker scan mutagenesis, a 17-bp RI site was identified as the key cis-element within the pN/H region. Data from electrophoretic mobility shift analysis and UV cross-linking experiments further indicated that a 45-kDa (p45) cell-specific transcription factor associates with RI in prostate cancer cells and may be responsible for driving the PSA promoter activity independent of androgen and AR. Furthermore, by juxtaposing AREc and pN/H, we produced a chimeric PSA promoter (supra-PSA) that exhibits 2-3-fold higher activity than the wild type PSA promoter in both LNCaP and C4-2 cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006269     DOI: 10.1074/jbc.M002755200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

2.  The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.

Authors:  Anthony J Saporita; Junkui Ai; Zhou Wang
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

3.  Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance.

Authors:  Sanjeev K Srivastava; Arun Bhardwaj; Seema Singh; Sumit Arora; Steven McClellan; William E Grizzle; Eddie Reed; Ajay P Singh
Journal:  Carcinogenesis       Date:  2012-03-19       Impact factor: 4.944

4.  The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.

Authors:  Patrice E Moss; Besstina E Lyles; LaMonica V Stewart
Journal:  Exp Cell Res       Date:  2010-10-13       Impact factor: 3.905

5.  Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase.

Authors:  Katsumi Shigemura; Shuji Isotani; Ruoxiang Wang; Masato Fujisawa; Akinobu Gotoh; Fray F Marshall; Haiyen E Zhau; Leland W K Chung
Journal:  Prostate       Date:  2009-06-15       Impact factor: 4.104

6.  Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1.

Authors:  Bhakti R Pathak; Ananya A Breed; Snehal Apte; Kshitish Acharya; Smita D Mahale
Journal:  Mol Cell Biochem       Date:  2015-09-14       Impact factor: 3.396

7.  Glucocorticoid receptor phosphorylation differentially affects target gene expression.

Authors:  Weiwei Chen; Thoa Dang; Raymond D Blind; Zhen Wang; Claudio N Cavasotto; Adam B Hittelman; Inez Rogatsky; Susan K Logan; Michael J Garabedian
Journal:  Mol Endocrinol       Date:  2008-05-15

8.  Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.

Authors:  Bekir Cinar; Fan Yeung; Hiroyuki Konaka; Marty W Mayo; Michael R Freeman; Haiyen E Zhau; Leland W K Chung
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

9.  Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells.

Authors:  Hongjuan Zhao; Rosalie Nolley; Zuxiong Chen; Stephen W Reese; Donna M Peehl
Journal:  Differentiation       Date:  2008-01-31       Impact factor: 3.880

10.  The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.

Authors:  Chih-Pin Chuu; Rou-Yu Chen; Richard A Hiipakka; John M Kokontis; Karen V Warner; Jialing Xiang; Shutsung Liao
Journal:  Biochem Biophys Res Commun       Date:  2007-03-28       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.